Trial Profile
A retrospective study of aflibercept in patients with treatment resistant neovascular age related macular degeneration (AMD), previously treated with ranibizumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Sep 2015
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 04 Sep 2015 New trial record